Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut
Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut
專注於呼吸道病毒感染的揭示生物科學公司轉向SPAC交易，首次亮相納斯達克
- Revelation Biosciences Inc is joining Petra Acquisition Inc (NASDAQ: PAIC) to create a NASDAQ-listed company with an enterprise value of $128 million.
- The merger is expected to close in Q4 2021, and the combined company will be listed on NASDAQ under the ticker symbol REVB.
- Revelation will pocket $73 million through the merger and use the money to advance REVTx-99, a nasal drop formulation designed to stimulate the innate immune system via TLR4-TRIF pathway agonism.
- In a 48-subject phase 1 trial, Revelation linked REVTx-99 to increased intranasal levels of the cytokine IP-10.
- Revelation identified IP-10 as the key cytokine of interest because it is upregulated in response to respiratory viral infection and linked to clinical efficacy in challenge studies.
- With phase 1 proof-of-principle data in hand, Revelation is now gearing up for further development.
- A 60-subject phase 2 influenza viral challenge study is slated to start in Q1 of 2022.
- REVTx-99 is also in development to treat chronic nasal congestion, with a phase 1 trial set to start this year.
- The same platform has generated a second, earlier-stage candidate, REVTx-200. Revelation sees the follow-up prospect as a way to improve the immune response to intramuscular vaccines.
- Price Action: PAIC stock is up 0.05% at $10.06 during the market session on the last check Monday.
- 啟示錄生物科學公司正在加入Petra Acquisition Inc.(納斯達克： 中國石油天然氣集團公司(PAIC：行情)創建一家納斯達克上市公司，企業價值1.28億美元.
- 合併預計將於2021年第四季度完成，合併後的公司將在納斯達克上市，股票代碼為REVB。
- 啟示會將通過合併獲得7300萬美元，並將這筆錢用於推進REVTx-99，這是一種滴鼻劑，旨在通過TLR4-TRIF途徑激動劑刺激先天免疫系統。
- 在48名受試者的第一階段試驗中，發現REVTx-99與鼻腔內細胞因子IP-10水平升高有關。
- 啟示錄確認IP-10是重要的細胞因子，因為它在應對呼吸道病毒感染時上調，並與挑戰研究中的臨牀療效有關。
- 有了第一階段的原則證明數據，啟示錄現在正在為進一步的發展做準備。
- 一項由60名受試者組成的第二階段流感病毒挑戰研究定於2022年第一季度開始。
- REVTx-99也在開發中，用於治療慢性鼻塞，第一階段試驗將於今年開始。
- 同一個平臺已經產生了第二個更早階段的候選者REVTx-200。啟示錄認為，後續的前景是改善對肌肉內疫苗的免疫反應的一種方式。
- 價格行動：在週一最後一次檢查的市場時段，Paic股價上漲0.05%，至10.06美元。